This site is intended for healthcare professionals. If you are a patient or caregiver, please contact your physician to discuss clinical trial eligibility.

Focused on the research and development of highly selective medicines for pediatric and adult patients with genomically defined cancers

At Loxo Oncology, we are focused on developing medicines that selectively inhibit a single cancer-driving molecular target. Our programs are designed to leverage recent advances in genomic testing to identify the patients most likely to benefit.

Explore our pipeline and clinical development programs to determine their ability to inhibit cancer-driving molecular targets in solid tumors and hematologic malignancies.

TRK Trials logo

Exploring new paths to tumor-agnostic selective TRK inhibition

For more information call:
1-855-NTRK-123

Learn More
RET Trials logo

Orchestrating a new investigational approach to researching RET-altered cancers

For more information call:
1-855-RET-4292

Learn More
BTK Trials logo

Researching a new strategy to address resistance and intolerance to covalent BTK inhibitors

For more information call:
1-855-LOXO-305

Learn More
    References:
  1. Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023.
  2. Ballerini P, Struski S, Cresson C, et al. RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. Leukemia. 2012;26(11):2384-2389.
  3. Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22(3):436-445.
  4. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18(3):375-377.
  5. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382-384.
  6. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378-381.
  7. Bossi D, Carlomagno F, Pallavicini I, et al. Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies. Mol Oncol. 2014;8(2):221-231.
  8. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846.
  9. Yoshihara K, Wang Q, Torres-Garcia W, et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2015;34(37):4845-4854.